INDUSTRY EXPERTS ARGUE CONFLICT OF INTEREST POLICIES’ PROS AND CONS AT EMA WORKSHOP
September 1st, 2013
A WORKSHOP held last week (Friday September 6th) to hear the views of interested parties on the conflicts of interest (COI) policies of the European Medicines Agency (EMA)has left the agency with a slew of sometimes conflicting opinions as it ponders the next step forward.The London-based agency was one of a number of European Union (EU) bodies criticised last year by the European Court of Auditors for unsatisfactory management of COI issues – a matter of some concern given the EMA’s significant decision-making powers in an area of key importance to the ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.